SLNCF — Silence Therapeutics Share News
0.000.00%
Last trade - 00:00- $902.88m
- $830.82m
- $0.56m
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing
Brief: Silence Therapeutics Announces Positive 36-Week Data From Ongoing Phase 2 Study Of Zerlasiran In Patients With High Lipoprotein(A)
Brief: Silence Therapeutics Receives $10 Million Milestone Payment From AstraZeneca Collaboration
Brief: Silence Therapeutics Achieves $10 Million Milestone Payment From Astrazeneca Collaboration
Brief: Silence Therapeutics Announces Preliminary Single Dose Results From SLN124 Phase 1 Study In Patients With Thalassemia
Brief: Silence Therapeutics Announces FDA Fast Track Designation For Sln124, A Novel Investigational Sirna Therapy For The Treatment Of Polycythemia Vera
NASDAQ RESUMED AT 10:32 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:27 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:35 AM
Brief: Silence Therapeutics PLC Says Cash And Cash Equivalents Of £73.5 Mln Is Sufficient To Fund Operations Through Early 2023
AIM - Cancellation - Silence Therapeutics Plc
Brief: Silence Therapeutics Updates On AIM Delisting
Silence Therapeutics - Update on AIM Delisting
Ftse Russell Silence Therapeutics Serica Energy Plc Pantheon Resources: Silence Therapeutics
Silence Therapeutics - Third Quarter 2021 Financial Results
Silence Therapeutics - Silence to Present at Jefferies London Conference